Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2015 | 128 | 1.450 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2024 | 182 | 1.090 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2026 | 3 | 0.980 |
Why?
|
| Calcinosis | 1 | 2026 | 53 | 0.930 |
Why?
|
| Myocarditis | 1 | 2026 | 52 | 0.910 |
Why?
|
| Cardiomyopathies | 1 | 2026 | 120 | 0.880 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2024 | 29 | 0.830 |
Why?
|
| bcl-X Protein | 3 | 2014 | 56 | 0.820 |
Why?
|
| Nuclear Medicine | 1 | 2024 | 23 | 0.810 |
Why?
|
| Cysts | 1 | 2024 | 53 | 0.810 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 48 | 0.800 |
Why?
|
| Medicine | 1 | 2024 | 51 | 0.800 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 401 | 0.640 |
Why?
|
| Apoptosis | 4 | 2015 | 1139 | 0.610 |
Why?
|
| Internship and Residency | 1 | 2024 | 439 | 0.580 |
Why?
|
| Sulfonamides | 3 | 2015 | 139 | 0.570 |
Why?
|
| Cyclin B1 | 2 | 2014 | 7 | 0.540 |
Why?
|
| Proteolysis | 2 | 2013 | 105 | 0.490 |
Why?
|
| Multiple Myeloma | 3 | 2025 | 3082 | 0.460 |
Why?
|
| Mitosis | 3 | 2013 | 86 | 0.440 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 32 | 0.440 |
Why?
|
| Nitrophenols | 1 | 2013 | 16 | 0.410 |
Why?
|
| Cell Survival | 3 | 2015 | 600 | 0.410 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 31 | 0.410 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 85 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 868 | 0.400 |
Why?
|
| Leukemia | 1 | 2013 | 67 | 0.390 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 141 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 1180 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 350 | 0.360 |
Why?
|
| HeLa Cells | 5 | 2015 | 243 | 0.350 |
Why?
|
| CDC2 Protein Kinase | 4 | 2014 | 15 | 0.340 |
Why?
|
| Humans | 19 | 2026 | 53230 | 0.330 |
Why?
|
| False Positive Reactions | 1 | 2026 | 66 | 0.240 |
Why?
|
| Phosphorylation | 4 | 2014 | 533 | 0.230 |
Why?
|
| Whole Body Imaging | 1 | 2025 | 25 | 0.220 |
Why?
|
| Malacoplakia | 1 | 2024 | 5 | 0.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 41 | 0.220 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 9 | 0.210 |
Why?
|
| Cricoid Cartilage | 1 | 2024 | 10 | 0.210 |
Why?
|
| Aniline Compounds | 2 | 2015 | 48 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 43 | 0.210 |
Why?
|
| Peripheral Nerves | 1 | 2024 | 43 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 28 | 0.210 |
Why?
|
| Caspase 3 | 2 | 2014 | 92 | 0.200 |
Why?
|
| Thyroid Gland | 1 | 2024 | 76 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 235 | 0.200 |
Why?
|
| Thyroid Dysgenesis | 1 | 2023 | 1 | 0.200 |
Why?
|
| Pheochromocytoma | 1 | 2023 | 34 | 0.200 |
Why?
|
| Sarcoidosis | 1 | 2024 | 44 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2023 | 49 | 0.200 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 274 | 0.200 |
Why?
|
| Prostate | 1 | 2024 | 118 | 0.200 |
Why?
|
| Hyperparathyroidism | 1 | 2023 | 30 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2023 | 27 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2025 | 212 | 0.190 |
Why?
|
| Radiography | 1 | 2024 | 476 | 0.190 |
Why?
|
| Adenoma | 1 | 2023 | 114 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 346 | 0.180 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 219 | 0.180 |
Why?
|
| Bone and Bones | 1 | 2025 | 501 | 0.170 |
Why?
|
| Kidney | 1 | 2024 | 715 | 0.160 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 149 | 0.150 |
Why?
|
| Immunoblotting | 2 | 2014 | 118 | 0.130 |
Why?
|
| Male | 4 | 2026 | 27435 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 85 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 1232 | 0.120 |
Why?
|
| Middle Aged | 3 | 2026 | 13419 | 0.110 |
Why?
|
| Vinblastine | 1 | 2014 | 22 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 28 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 26 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 56 | 0.100 |
Why?
|
| Transfection | 1 | 2014 | 359 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 92 | 0.100 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2014 | 21 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 35 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 109 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 150 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2013 | 267 | 0.100 |
Why?
|
| Cell Death | 1 | 2013 | 171 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 175 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1350 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5409 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2014 | 587 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2013 | 237 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2014 | 333 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 1470 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2014 | 1748 | 0.080 |
Why?
|
| CTLA-4 Antigen | 1 | 2025 | 32 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 46 | 0.060 |
Why?
|
| Animals | 2 | 2025 | 13526 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 89 | 0.060 |
Why?
|
| Retroperitoneal Space | 1 | 2024 | 26 | 0.060 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 17 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 145 | 0.050 |
Why?
|
| Extremities | 1 | 2024 | 36 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 237 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2023 | 31 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2023 | 38 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2023 | 20 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2023 | 18 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2025 | 266 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 107 | 0.050 |
Why?
|
| Female | 4 | 2025 | 28782 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 198 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 298 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1038 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2025 | 6819 | 0.040 |
Why?
|
| Aged | 2 | 2025 | 10429 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2021 | 95 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1517 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1925 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2021 | 223 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 934 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1212 | 0.030 |
Why?
|
| Mice | 1 | 2025 | 5982 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 75 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 136 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2012 | 90 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 91 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 140 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 400 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 282 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 607 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 737 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 14534 | 0.020 |
Why?
|